[at noodls] – AstraZeneca today announced that the Federal Patent Court in Germany has found the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets – marketed as SEROQUEL Prolong … moreView todays social media effects on AZNView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David MoskowitzNektar Therapeutics (NASDAQ:NKTR) hosted a conference call Monday morning, highlighting the successful results from two Phase III trials and one safety extension study for Naloxegol, … moreView todays social media effects on AZNView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – AstraZeneca is today making a regulatory disclosure following the grant of share awards to the company’s new Chief Executive Officer Pascal Soriot in compensation for the forfeiture of long-term incentives … moreView todays social media effects on AZNView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingDespite a stash of cash and liquid investments, Lexicon Pharmaceuticals (NASDAQ:LXRX) caught investors off guard two weeks ago by initiating a capital raise. The company had more than $225M … moreView todays social media effects on AZNView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jason Napodano, CFAOn October 22, 2012, Pozen (NASDAQ:POZN) presented a full analysis of the integrated results of its two Phase 3 studies comparing PA-325/40 (EC-ASA 325 mg + IR omeprazole 40 mg) to … moreView todays social media effects on AZNView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – AstraZeneca and Ironwood Pharmaceuticals, Inc. announced today an agreement to co-develop and co-commercialise Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) … moreView todays social media effects on AZNView the latest stocks trending across Twitter. Click to view dashboard […]
